**NON-CONFIDENTIAL**

**INVESTMENT SUBMISSION COVER PAGE**

Prior to submitting an investment opportunity to MABA, please first review our Investment Criteria document – to ensure that there is a fit, and attach this cover page to your executive summary (which should not exceed three pages).

***Please make sure that this application contains only non-confidential information.***

**MABA members include both individuals, as well as corporations. *Please do not provide any information you would not want seen by such entities.***

***Also, please be aware of MABA’s Presenting Company Warrant Requirements:***

Instead of charging companies a cash fee to present (as some other groups do), if the presentation to MABA results in at least $250,000 investment we ask for the right to invest no more than $30,000, on the same terms as our investors, but have seven years to make that investment (exercise the warrants).

1. The warrants are not free – they are priced at whatever the MABA investors pay for their shares.

2. They are for a limited amount - $30,000.

3. If the presentation to MABA does not result in an investment of at least $250,000, the warrants automatically terminate.

4. The warrants are for common stock.

5. A company that has received at least $250,000 can discharge the warrants with a $5,000 payment, within 30 days of receiving the investment.

Please let us know if you have any questions or concerns about this requirement.

**By submitting an application, you acknowledge your acceptance of the terms noted above.**

If your company is selected by the Screening Committee to present, we will send you a Presenting Company Agreement. Companies will be scheduled to present upon receipt of their signed Agreement, on a first come, first serve basis.

We look forward to receiving your submission.

|  |  |
| --- | --- |
| 1. Name of company (plus website – if any)
 |  |
| 1. Name of main contact (name, title, phone(s) & email)
 |  |
| 1. Location of company (if virtual, location of main contact)
 |  |
| **INTRODUCTION** |  |
| 1. What is the problem your company is trying to solve?
 |  |
| 1. Please describe your company’s solution to the problem, above, in plain English.
 |  |
| 1. Company start-up date
 |  |
| **FUNDING** |  |
| 1. Amount of money previously raised (total)
 |  |
| 1. Date last round closed
 |  |
| 1. Post-money valuation at the last round
 |  |
| 1. Amount of money being raised in current round
 |  |
| 1. Terms of current round (note/priced, discounts & caps), including pre-money valuation
 |  |
| 1. Date current round began & amount of money invested so far
 |  |
| 1. Including the current round, how much more investment capital will be required (including ***all*** ***future rounds*** and not including grants or other non-dilutive funding)?
 |  |
| 1. Minimum and Maximum amount of money available for MABA to invest in this round
 |  |
| 1. Where will your future funding (after this round) come from? Please include both dilutive and non-dilutive sources.
 |  |
| 1. What event will render further funding unnecessary (e.g., licensing deal, breakeven achieved, other) – and time to reach that event?
 |  |
| 1. Exit: What will an expected exit look like (type, timing, comps, ROI)?
 |  |
| 1. Describe non-dilutive or grant funding already received or applied for (please differentiate between received and applied for)
 |  |
| **PRODUCT** |  |
| 1. Is this a single product/service or a platform?
 |  |
| 1. If the company has developed a platform, what is the first product/service to be marketed commercially?
 |  |
| 1. Please provide a ***non-confidential*** description of how your product works
 |  |
| 1. Please provide data in support of the product’s efficacy
 |  |
| 1. Please indicate at least one significant publication that you believe supports your technology. (Be specific. If possible, please attach to submission)
 |  |
| 1. Are there toxicity or other issues associated with your product?
 |  |
| 1. Please list the reasons your product is superior to the standard of care, and to competitors’ products (including those pending approval)
 |  |
| 1. Current development stage (of first product/service)
 |  |
| 1. Briefly describe how product/device will be manufactured
 |  |
| **MARKET** |  |
| 1. Total addressable market (if platform – for first product only)
 |  |
| 1. Please identify all your known competitors
 |  |
| 1. In addition to patients, please identify all entities (doctors, hospitals, insurance companies, etc.) that would benefit from your product – financially and otherwise, please indicate how they would benefit, and their reasons to support the product’s adoption
 |  |
| 1. Sales and Go-to-Market Strategy
 |  |
| 1. If already selling – annual $ sales and number of customers
 |  |
| 1. Please identify current & anticipated alliance partners (please be specific)
 |  |
| **INTELLECTUAL PROPERTY (IP)** |  |
| 1. Describe the status and scope of patent protection, if any (number of applications, nature of claims, when filed/granted)
 |  |
| 1. Is there other IP – that might affect the product/service?
 |  |
| 1. Who owns the patents and other IP, if any?
 |  |
| 1. Describe the competitive IP landscape and how the company’s IP fits within that landscape
 |  |
| **REGULATORY & REIMBURSEMENT** |  |
| 1. FDA strategy, time to approval of primary indication/first product and approval pathway
 |  |
| 1. Reimbursement strategy (one sentence)
 |  |
| **TEAM** |  |
| 1. Management team (P&L/operating experience, significant accomplishments, prior fundraising experience and return to investors (If any))
 |  |
| 1. Endorsement(s)/key supporters/key opinion leaders (specific names)
 |  |
| 1. Professional advisors (specific names) (legal, accounting, regulatory consultants, others?)
 |  |
| 1. Describe ***all*** special deals and circumstances with and between partners, related parties and anyone else (grant backs to founders, special licenses, etc.)
 |  |
| 1. Current salary and other compensation for each executive. How/will it change after financing?
 |  |
| 1. Is the team complete? What functions / capabilities are needed, and when will they be added? Have people already been identified for these positions?
 |  |
| 1. Are any of the team members related to one another (if so, how)?
 |  |
| **MISCELLANEOUS** |  |
| 1. How can investors lose their money? What are the biggest risks (competitive, regulatory, technical, etc.) standing between the company and successful commercialization and exit?
 |  |
| 1. Anticipated use of funds from this point forward
 |  |
| 1. How did you hear of MABA?
 |  |
| 1. If you have a short video (<5min) that you would like to share, please provide the link here.
 |  |
| 1. If you have applied to MABA in the past and were rejected, please list the reasons given for your rejection, and why these no longer apply.
 |  |

Please return this completed document – ***in PDF format and* *with your company name incorporated into the document name***, along with an executive summary, and other relevant documents, to: info@bioangels.net. Please make sure that your company name is in the subject line.

Thank you.

Mid Atlantic Bio Angels (MABA)